Novel molecular perspectives for the treatment of recurrent anaplastic meningiomas : a case report.

Nuevas perspectivas moleculares para el tratamiento de los meningiomas anaplásicos recurrentes : a propósito de un caso.

Published 2013-10-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 2 No. 3 (2013): Octubre
Section
Clinic cases
How to Cite
Novel molecular perspectives for the treatment of recurrent anaplastic meningiomas : a case report.
Rev. colomb. hematol. oncol. [Internet]. 2013 Oct. 1 [cited 2024 Dec. 22];2(3):40-4. Disponible en: https://doi.org/10.51643/22562915.352
DOI

https://doi.org/10.51643/22562915.352
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

José M. Behaine
Universidad El Bosque ; Fundación Santa Fe de Bogotá
    Juan Armando Mejía
    Universidad El Bosque ; Fundación Santa Fe de Bogotá
      Nicolás Useche
      Universidad El Bosque ; Fundación Santa Fe de Bogotá
        Sonia Bermúdez
        Universidad El Bosque ; Fundación Santa Fe de Bogotá
          Andrés Felipe Cardona
          Universidad El Bosque ; Fundación para la Investigación Clínica y Molecular Aplicada del Cáncer (FICMAC) ; Fundación Santa Fe de Bogotá
            Show authors biography

            José M. Behaine,

            Instituto de Neurociencias, Universidad El Bosque (Bogotá, Colombia). Departamento de Neurocirugía, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

            Juan Armando Mejía,

            Instituto de Neurociencias, Universidad El Bosque (Bogotá, Colombia). Departamento de Neurocirugía, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

            Nicolás Useche,

            Instituto de Neurociencias, Universidad El Bosque (Bogotá, Colombia). Departamento de Imágenes Diagnósticas, Sección Neurorradiología, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

            Sonia Bermúdez,

            Instituto de Neurociencias, Universidad El Bosque (Bogotá, Colombia). Departamento de Imágenes Diagnósticas, Sección Neurorradiología, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

            Andrés Felipe Cardona,

            Instituto de Neurociencias, Universidad El Bosque (Bogotá, Colombia). Grupo de Oncología Clínica y Traslacional, Instituto de Oncología, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Fundación para la Investigación Clínica y Molecular Aplicada al Cáncer (FICMAC); Investigador asociado ONCOLGroup (Bogotá, Colombia.

            A 53-year-old woman who presented behavioral changes with attention and affection disturbances due to the diagnosis of a high grade meningioma requiring multiple surgeries followed by radiotherapy, hydroxyurea and imatinib; thereafter, the lesion progressed considering the use of octreotide plus everolimus to modulate the abnormal somatostatin receptor expression as well as the altered transcription by PIP3K/mTOR/AKT pathway. With this treatment the patient obtained a durable partial reponse.

            Article visits 123 | PDF visits 230

            1. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery. 2005;57(3):538-50.
            2. Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol. 2010;99(3):433-43.
            3. Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007;23(4):E12.
            4. Schulz C, Mathieu R, Kunz U, Mauer UM. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011;30(5):E11.
            5. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285-9.
            6. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1 and SMO. Science. 2013;339(6123):1077-80.
            7. Jhonson MD, O’Conell M, Vito F, Bacos RS. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol. 2009;92(2):129-36.
            8. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010;99(3):365-78.
            9. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530-5.
            10. Barlier A, Graillon T, Defilles C, Mohamend A, Saveanu A. 419PD STRONG Additive effect of everolimus and octreotide or pasireotide on meningioma cells in vitro: a new therapeutic strategy for these tumors. Ann Oncol. 2012;23(suppl 9):ix144-51.
            11. Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res. 2013;19(5):1180-9.
            12. Lattuada D, Casnici C, Venuto A, Marelli O. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. J Neuroimmunol. 2002;133(1-2):211-6.
            13. Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, et al. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008;27(5):334-45.
            14. Lamar Z, Lesser GJ. Management of meningeal neoplasms: meningiomas and hemangiopericytomas. Curr Treat Options Oncol. 2011;12(3):230-9.
            15. Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJ, Bergström M, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27(4):416-9.
            16. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94(3):487-92.
            17. Drake WM, Grossman AB, Hutson RK. Effect of treatment with pegvisomant on meningioma growth in vivo. Eur J Endocrinol. 2005;152(1):161-2.
            18. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;66(1-2):155-66.
            19. Shih K, Rosenblatt P, Chowdhary SA, Weir A, Shepard G, Shastry M, et al. Combination of bevacizumab and everolimus in patients with refractory, progressive intracranial meningioma: a phase II trial of the Sarah cannon research institute. Neurooncology. 2012;14(suppl 6):vi101-5.
            20. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969-73.
            21. Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998;39(11):1913-7.
            22. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133-40.
            23. Hanakita S, Koga T, Igaki H, Murakami N, Oya S, Shin M, et al. Role of Gamma Knife surgery for intracranial atypical (WHO Grade II) meningiomas. J Neurosurg. 2013;119(6):1410-4.
            24. Hou J, Kshettry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35(6):E2.
            25. Wang S, Yang W, Deng J, Zhang J, Ma F, Wang J. Reduction in the recurrence of meningiomas by combining somatostatin receptor scintigraphy of (99m)Tc-HYNIC-octreotide SPECT/CT and radio guidance with a hand-held g-probe during surgery. Nucl Med Commun. 2013;34(3):249-53.
            26. Bernal L, Cardona AF, Useche N, Bartels C, Bermúdez S, Jiménez E, et al. Terapia dirigida en meningiomas: genómica con nuevas perspectivas. RedLANO e-Journal 2013.
            27. Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus. 2013;35 (6):E18.
            28. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)c]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269-76.

            Information

            Directories and indexers
            Google Scholar profile

            QR code

            Keywords

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |